The recognition of primary membranous nephropathy (pMN) as an autoantibody-driven disease and the identification of podocyte target antigens have been major advances in the diagnosis, prognosis, and management of pMN and support the use of B-cell depleting agents such as rituximab. However, many patients do not respond to rituximab, and others who respond experience relapse. Second-generation anti-CD20 agents and other B-cell targeting agents are in development for pMN. This expert discussion will highlight the need for and how emerging B-cell targeted therapies may be incorporated into the treatment of pMN.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
97% of listed courses are free
34 of 35 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Communication & Shared Decision-Making
- Dermatology
- Gastroenterology
- General Pediatrics
- Hematology
- Medical Oncology
- Nephrology
- Obstetrics & Gynecology
- Ophthalmology
- Orthopaedic Surgery
- Psychotic Disorders
- Rheumatology
- Surgical Oncology
- Cross-Specialty
- GI & Liver
- Medical Subspecialties
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pathology & Lab
- Pediatrics
- Psychiatry
- Surgery
- No reviews yet. Be the first to share yours.
- Enduring / On-demand
- Credit · Up to 1 credit
- Paid · fee on provider site
- Commercial Support
-
ReleasedApr 30, 2026
-
Last day to claim creditMay 1, 2027 7 months left
-
i3 Health Exploring the Use of Biologics in the Management of Lupus Nephritis: A Clinical Case Conference
-
Answers in CME Inc. (AiCME) Emerging Therapeutic Options for Lupus Nephritis: Preserving Kidney Function and Delaying Progression
-
Medscape, LLC Translating Emerging Evidence in IgA Nephropathy: Proteinuria and eGFR as Biomarkers of Disease Progression
-
Paradigm Medical Communications, LLC New Paradigms Podcast: New and Emerging Mechanisms in the Treatment of SLE
-
Paradigm Medical Communications, LLC Advancements in Idiopathic Nephrotic Syndrome: Updates on Clinical Trial Data and Management
-
Paradigm Medical Communications, LLC Incorporating New Data Into Patient Care for Lupus Nephritis
